413 related articles for article (PubMed ID: 37020315)
1. Liver-HERO: hepatorenal syndrome-acute kidney injury (HRS-AKI) treatment with transjugular intrahepatic portosystemic shunt in patients with cirrhosis-a randomized controlled trial.
Ripoll C; Platzer S; Franken P; Aschenbach R; Wienke A; Schuhmacher U; Teichgräber U; Stallmach A; Steighardt J; Zipprich A;
Trials; 2023 Apr; 24(1):258. PubMed ID: 37020315
[TBL] [Abstract][Full Text] [Related]
2. Transjugular intrahepatic portosystemic shunts for adults with hepatorenal syndrome.
Gonzalez-Garay AG; Serralde-Zúñiga AE; Velasco Hidalgo L; Flores García NC; Aguirre-Salgado MI
Cochrane Database Syst Rev; 2024 Jan; 1(1):CD011039. PubMed ID: 38235907
[TBL] [Abstract][Full Text] [Related]
3. AGA Clinical Practice Update on the Use of Vasoactive Drugs and Intravenous Albumin in Cirrhosis: Expert Review.
Garcia-Tsao G; Abraldes JG; Rich NE; Wong VW
Gastroenterology; 2024 Jan; 166(1):202-210. PubMed ID: 37978969
[TBL] [Abstract][Full Text] [Related]
4. AGA Clinical Practice Update on the Evaluation and Management of Acute Kidney Injury in Patients With Cirrhosis: Expert Review.
Flamm SL; Wong F; Ahn J; Kamath PS
Clin Gastroenterol Hepatol; 2022 Dec; 20(12):2707-2716. PubMed ID: 36075500
[TBL] [Abstract][Full Text] [Related]
5. Early TIPS with covered stents versus standard treatment for acute variceal bleeding in patients with advanced cirrhosis: a randomised controlled trial.
Lv Y; Yang Z; Liu L; Li K; He C; Wang Z; Bai W; Guo W; Yu T; Yuan X; Zhang H; Xie H; Yao L; Wang J; Li T; Wang Q; Chen H; Wang E; Xia D; Luo B; Li X; Yuan J; Han N; Zhu Y; Niu J; Cai H; Xia J; Yin Z; Wu K; Fan D; Han G;
Lancet Gastroenterol Hepatol; 2019 Aug; 4(8):587-598. PubMed ID: 31153882
[TBL] [Abstract][Full Text] [Related]
6. Acute kidney injury and hepatorenal syndrome in cirrhosis.
Egerod Israelsen M; Gluud LL; Krag A
J Gastroenterol Hepatol; 2015 Feb; 30(2):236-43. PubMed ID: 25160511
[TBL] [Abstract][Full Text] [Related]
7. Management of ascites and hepatorenal syndrome.
Piano S; Tonon M; Angeli P
Hepatol Int; 2018 Feb; 12(Suppl 1):122-134. PubMed ID: 28836115
[TBL] [Abstract][Full Text] [Related]
8. Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1.
Boyer TD; Sanyal AJ; Wong F; Frederick RT; Lake JR; O'Leary JG; Ganger D; Jamil K; Pappas SC;
Gastroenterology; 2016 Jun; 150(7):1579-1589.e2. PubMed ID: 26896734
[TBL] [Abstract][Full Text] [Related]
9. The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension.
Colombato L
J Clin Gastroenterol; 2007; 41 Suppl 3():S344-51. PubMed ID: 17975487
[TBL] [Abstract][Full Text] [Related]
10. Update in the Treatment of the Complications of Cirrhosis.
Abraldes JG; Caraceni P; Ghabril M; Garcia-Tsao G
Clin Gastroenterol Hepatol; 2023 Jul; 21(8):2100-2109. PubMed ID: 36972759
[TBL] [Abstract][Full Text] [Related]
11. Surgical portosystemic shunts versus transjugular intrahepatic portosystemic shunt for variceal haemorrhage in people with cirrhosis.
Brand M; Prodehl L; Ede CJ
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD001023. PubMed ID: 30378107
[TBL] [Abstract][Full Text] [Related]
12. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation.
Testino G; Ferro C; Sumberaz A; Messa P; Morelli N; Guadagni B; Ardizzone G; Valente U
Hepatogastroenterology; 2003; 50(54):1753-5. PubMed ID: 14696397
[TBL] [Abstract][Full Text] [Related]
13. The role of transjugular intrahepatic portosystemic shunt in patients with portal hypertension: Advantages and pitfalls.
Lee HL; Lee SW
Clin Mol Hepatol; 2022 Apr; 28(2):121-134. PubMed ID: 34571587
[TBL] [Abstract][Full Text] [Related]
14. TIPS for management of portal-hypertension-related complications in patients with cirrhosis.
Allaire M; Walter A; Sutter O; Nahon P; Ganne-Carrié N; Amathieu R; Nault JC
Clin Res Hepatol Gastroenterol; 2020 Jun; 44(3):249-263. PubMed ID: 31662286
[TBL] [Abstract][Full Text] [Related]
15. Transjugular intrahepatic portosystemic shunt: current status.
Boyer TD
Gastroenterology; 2003 May; 124(6):1700-10. PubMed ID: 12761727
[TBL] [Abstract][Full Text] [Related]
16. Morbidity and mortality after transjugular intrahepatic portosystemic shunt placement in patients with cirrhosis.
Dissegna D; Sponza M; Falleti E; Fabris C; Vit A; Angeli P; Piano S; Cussigh A; Cmet S; Toniutto P
Eur J Gastroenterol Hepatol; 2019 May; 31(5):626-632. PubMed ID: 30550458
[TBL] [Abstract][Full Text] [Related]
17. Transjugular Intrahepatic Portosystemic Shunts With Covered Stents Increase Transplant-Free Survival of Patients With Cirrhosis and Recurrent Ascites.
Bureau C; Thabut D; Oberti F; Dharancy S; Carbonell N; Bouvier A; Mathurin P; Otal P; Cabarrou P; Péron JM; Vinel JP
Gastroenterology; 2017 Jan; 152(1):157-163. PubMed ID: 27663604
[TBL] [Abstract][Full Text] [Related]
18. Transjugular intrahepatic portosystemic shunt in cirrhosis: An exhaustive critical update.
Rajesh S; George T; Philips CA; Ahamed R; Kumbar S; Mohan N; Mohanan M; Augustine P
World J Gastroenterol; 2020 Oct; 26(37):5561-5596. PubMed ID: 33088154
[TBL] [Abstract][Full Text] [Related]
19. Transjugular intrahepatic portosystemic shunts and portal hypertension-related complications.
Siramolpiwat S
World J Gastroenterol; 2014 Dec; 20(45):16996-7010. PubMed ID: 25493012
[TBL] [Abstract][Full Text] [Related]
20. [Hepatorenal syndrome: diagnosis, treatment and prevention].
Egerod Israelsen M; Gluud LL; Bendtsen F; Møller S; Krag AA
Ugeskr Laeger; 2013 May; 175(22):1562-6. PubMed ID: 23721840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
